NCT06531083 Feasibility of Prospective Surveillance and Early Physical Therapy for Trismus
| NCT ID | NCT06531083 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Head and Neck Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-03-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Trismus, or restricted jaw movement, can occur in individuals with head and neck cancer (HNC) undergoing surgery or radiation therapy. There is a paucity of research examining interventions for trismus. We aim to assess the feasibility of prospective surveillance and early intervention to mitigate trismus in individuals undergoing HNC treatment. Method: The investigators will conduct a pilot single group feasibility study involving 30 individuals with HNC who will be undergoing radiation therapy. Participants will be identified at the HNC new patient clinic. Participants will be seen weekly during radiation therapy and will receive early intervention including manual therapy and a device-based jaw exercise regimen if presenting with 5% or greater reduction in jaw opening compared to pre-treatment. The investigators will assess recruitment and completion rates, intervention acceptability, and data collection procedures. Descriptive statistics will summarize feasibility metrics and participant demographics. Findings will inform the design of a larger multicentre trial.
Eligibility Criteria
Inclusion Criteria: * Have a diagnosis of oral, oropharyngeal, or nasopharyngeal cancer * Be scheduled to undergo cancer treatment that includes radiation therapy * Be able to read and understand English * Be an Alberta resident. Exclusion Criteria: * Previous surgery for the temporomandibular joint that is not related to the HNC diagnosis. * Local cancer recurrence or metastatic disease. * Unable to provide informed consent.
Contact & Investigator
Margaret McNeely, PhD
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT06531083 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06531083 currently recruiting?
Yes, NCT06531083 is actively recruiting participants. Contact the research team at mmcneely@ualberta.ca for enrollment information.
Where is the NCT06531083 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT06531083 clinical trial?
NCT06531083 is sponsored by University of Alberta. The principal investigator is Margaret McNeely, PhD at University of Alberta. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.